How to buy NovoCure stock | $170.09

NovoCure Limited is a medical instruments & supplies business based in the US. NovoCure shares (NVCR) are listed on the NASDAQ and all prices are listed in US Dollars. NovoCure employs 782 staff and has a trailing 12-month revenue of around USD$449.6 million.

How to buy shares in NovoCure

1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
3. Search for NovoCure. Find the stock by name or ticker symbol: NVCR. Research its history to confirm it's a solid investment against your financial goals.
4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until NovoCure reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
5. Decide on how many to buy. At last close price of USD$170.09, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of NovoCure, depending on your broker.
6. Check in on your investment. Congratulations, you own a part of NovoCure. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

NovoCure share price

Use our graph to track the performance of NVCR stocks over time.

NovoCure shares at a glance

• Key figures

Information last updated 2021-01-13.

Latest market close	USD$170.09
52-week range	USD$53.4 - USD$180.97
50-day moving average	USD$156.8385
200-day moving average	USD$110.6133
Wall St. target price	USD$136
PE ratio	955.4891
Dividend yield	N/A (0%)
Earnings per share (TTM)	USD$0.184

Buy NovoCure shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

Is it a good time to buy NovoCure stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of NovoCure Limited by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

NovoCure price performance over time

Historical closes compared with the close of $170.09 from 2021-01-11

1 week (2021-01-07)	3.97%
1 month (2020-12-17)	4.47%
3 months (2020-10-16)	24.19%
6 months (2020-07-17)	169.39%

1 year (2020-01-17)	83.72%
2 years (2019-01-17)	275.72%
3 years (2018-01-17)	719.71%
5 years (2016-01-15)	856.10%

Is NovoCure under- or over-valued?

Valuing NovoCure stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of NovoCure's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

NovoCure's P/E ratio

NovoCure's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 955x. In other words, NovoCure shares trade at around 955x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

NovoCure's EBITDA

NovoCure's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$26.3 million.

The EBITDA is a measure of a NovoCure's overall financial performance and is widely used to measure a its profitability.

NovoCure financials

Revenue TTM	USD$449.6 million
Operating margin TTM	4.18%
Gross profit TTM	USD$263 million
Return on assets TTM	2.68%
Return on equity TTM	7.7%
Profit margin	4.26%
Book value	$3.018
Market capitalisation	USD$17.9 billion

TTM: trailing 12 months

Shorting NovoCure shares

There are currently 5.9 million NovoCure shares held short by investors – that's known as NovoCure's "short interest". This figure is 17.8% up from 5.0 million last month.

There are a few different ways that this level of interest in shorting NovoCure shares can be evaluated.

NovoCure's "short interest ratio" (SIR)

NovoCure's "short interest ratio" (SIR) is the quantity of NovoCure shares currently shorted divided by the average quantity of NovoCure shares traded daily (recently around 1.5 million). NovoCure's SIR currently stands at 3.95. In other words for every 100,000 NovoCure shares traded daily on the market, roughly 3950 shares are currently held short.

However NovoCure's short interest can also be evaluated against the total number of NovoCure shares, or, against the total number of tradable NovoCure shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case NovoCure's short interest could be expressed as 0.05% of the outstanding shares (for every 100,000 NovoCure shares in existence, roughly 50 shares are currently held short) or 0.0608% of the tradable shares (for every 100,000 tradable NovoCure shares, roughly 61 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against NovoCure.

Find out more about how you can short NovoCure stock.

NovoCure share dividends

We're not expecting NovoCure to pay a dividend over the next 12 months.

NovoCure share price volatility

Over the last 12 months, NovoCure's shares have ranged in value from as little as $53.4 up to $180.97. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while NovoCure's is 1.2836. This would suggest that NovoCure's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

NovoCure overview

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. The company markets Optune and NovoTTF-100L, a Tumor Treating Fields delivery system for use as a monotherapy treatment for adult patients with glioblastoma. It is also developing products that are in Phase 2 pilot and Phase 3 pivotal trials for brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer, liver cancer, and mesothelioma. The company markets its products in the European Union, Japan, and internationally. It has a clinical trial collaboration agreement with MSD to evaluate tumor treating fields together with KEYTRUDA, an anti-PD-1 therapy; and a strategic alliance with the NYU Grossman School of Medicine's Department of Radiation Oncology that provides a framework for preclinical and clinical development projects studying Tumor Treating Fields. NovoCure Limited was founded in 2000 and is based in Saint Helier, Jersey.

Frequently asked questions

• What percentage of NovoCure is owned by insiders or institutions?

  Currently 14.821% of NovoCure shares are held by insiders and 82.912% by institutions.

• How many people work for NovoCure?

  Latest data suggests 782 work at NovoCure.

• When does the fiscal year end for NovoCure?

  NovoCure's fiscal year ends in December.

• Where is NovoCure based?

  NovoCure's address is: No. 4 The Forum, Saint Helier, Jersey, JE2 4UF

• What is NovoCure's ISIN number?

  NovoCure's international securities identification number is: JE00BYSS4X48

• What is NovoCure's CUSIP number?

  NovoCure's Committee on Uniform Securities Identification Procedures number is: G6674U108